.png)
Evotec’s mission is to discover and develop highly effective therapeutics and make them globally available to the patients who need them. To this end, Evotec has established itself as a global platform company, leveraging its data-driven multimodality platform for both proprietary as well as partnered research, and applying a unique combination of innovative technologies for the discovery and development of first-in-class and best-in-class pharmaceutical products. Its network of partners includes all Top 20 Pharma and hundreds of biotechnology companies, academic institutions, and other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and make them accessible to patients worldwide. To-date, the Company has established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.
Evotec operates globally with more than 5,000 highly qualified people at 17 sites in six countries across Europe and the USA. The Company’s sites in Hamburg (HQ), Cologne, Göttingen, Halle/Westphalia and Munich (Germany), Lyon and Toulouse (France), Abingdon and Alderley Park (UK), Modena and Verona (Italy), Orth (Austria), as well as in Branford, Princeton, Redmond, Seattle and Framingham (USA) offer highly synergistic technologies and services and operate as complementary clusters of excellence.